POXEL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.473 EUR | -0.94% |
|
+12.22% | -9.56% |
| Jul. 15 | Poxel: financing discussions being finalized | CF |
| Apr. 11 | Poxel: CDC falls below the 10% threshold | CF |
| Sales 2021 | 13.4M 14.61M | Sales 2022 | 674K 735K | Capitalization | 27.16M 29.61M |
|---|---|---|---|---|---|
| Net income 2021 | -23M -25.08M | Net income 2022 | -31M -33.8M | EV / Sales 2021 | 10.7 x |
| Net Debt 2021 | 3M 3.28M | Net Debt 2022 | 32.74M 35.69M | EV / Sales 2022 | 88.9 x |
| P/E ratio 2021 |
-5.92
x | P/E ratio 2022 |
-0.87
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Poxel
More press releases
More news
| 1 week | +12.22% | ||
| Current month | +5.58% | ||
| 1 month | -7.62% | ||
| 3 months | -20.64% | ||
| 6 months | +13.43% | ||
| Current year | -9.56% |
1 week
0.42
0.50
1 month
0.420.54
3 years
0.276.71
5 years
0.2713.56
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 61 | 09-03-05 | |
Sebastien Bolze
FOU | Founder | - | 09-03-05 |
| Founder | - | 09-03-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Kender
BRD | Director/Board Member | 68 | 15-03-11 |
Pascale Boissel
BRD | Director/Board Member | 57 | 15-03-04 |
Thomas Kuhn
FOU | Founder | 50 | 09-03-05 |
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.473 | -0.94% |
| 24-07-15 | 0.4775 | +5.64% |
| 24-07-12 | 0.452 | +3.43% |
| 24-07-11 | 0.437 | +1.98% |
| 24-07-10 | 0.4285 | +1.66% |
Delayed Quote Börse Stuttgart, July 16, 2024 at 09:35 am EDT
More quotes
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
2024-08-28
- Q2 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| +20.17% | 126B | |
| +24.67% | 118B | |
| +25.44% | 27.87B | |
| -17.74% | 20.95B | |
| -15.17% | 16.92B | |
| -15.21% | 16.18B | |
| +11.91% | 14.84B | |
| -47.10% | 14.79B | |
| +54.50% | 14.08B |
- Stock Market
- Equities
- POXEL Stock
- 7PO Stock
